12 results on '"Oliver, Tim"'
Search Results
2. The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer.
- Author
-
Davies, Caitlin R., Tianyu Guo, Burke, Edwina, Stankiewicz, Elzbieta, Lei Xu, Mao, Xueying, Scandura, Glenda, Rajan, Prabhakar, Tipples, Karen, Alifrangis, Constantine, Wimalasingham, Akhila Ganeshi, Galazi, Myria, Crusz, Shanthini, Powles, Thomas, Grey, Alistair, Oliver, Tim, Kudahetti, Sakunthala, Shaw, Greg, Berney, Daniel, and Shamash, Jonathan
- Subjects
PROSTATE cancer ,DOCETAXEL ,GENE expression ,METASTASIS ,CASTRATION-resistant prostate cancer ,PROGRESSION-free survival - Abstract
Background: Docetaxel improves overall survival (OS) in castration-resistant prostate cancer (PCa) (CRPC) and metastatic hormone-sensitive PCa (mHSPC). However, not all patients respond due to inherent and/or acquired resistance. There remains an unmet clinical need for a robust predictive test to stratify patients for treatment. Liquid biopsy of circulating tumour cell (CTCs) is minimally invasive, can provide real-time information of the heterogeneous tumour and therefore may be a potentially ideal docetaxel response prediction biomarker. Objective: In this study we investigate the potential of using CTCs and their gene expression to predict post-docetaxel tumour response, OS and progression free survival (PFS). Methods: Peripheral blood was sampled from 18 mCRPC and 43 mHSPC patients, pre-docetaxel treatment, for CTC investigation. CTCs were isolated ® using the epitope independent Parsortix system and gene expression was determined by multiplex RT-qPCR. We evaluated CTC measurements for post-docetaxel outcome prediction using receiver operating characteristics and Kaplan Meier analysis. Results: Detection of CTCs pre-docetaxel was associated with poor patient outcome post-docetaxel treatment. Combining total-CTC number with PSA and ALP predicted lack of partial response (PR) with an AUC of 0.90, p= 0.037 in mCRPC. A significantly shorter median OS was seen in mCRPC patients with positive CTC-score (12.80 vs. 37.33 months, HR= 5.08, p= 0.0005), ≥3 total-CTCs/7.5mL (12.80 vs. 37.33 months, HR= 3.84, p= 0.0053), ≥1 epithelial-CTCs/7.5mL (14.30 vs. 37.33 months, HR= 3.89, p= 0.0041) or epithelial to mesenchymal transitioning (EMTing)-CTCs/7.5mL (11.32 vs. 32.37 months, HR= 6.73, p= 0.0001). Significantly shorter PFS was observed in patients with ≥2 epithelial-CTCs/7.5mL (7.52 vs. 18.83 months, HR= 3.93, p= 0.0058). mHSPC patients with ≥5 CTCs/7.5mL had significantly shorter median OS (24.57 vs undefined months, HR= 4.14, p= 0.0097). In mHSPC patients, expression of KLK2, KLK4, ADAMTS1, ZEB1 and SNAI1 was significantly associated with shorter OS and/or PFS. Importantly, combining CTC measurements with clinical biomarkers increased sensitivity and specificity for prediction of patient outcome. Conclusion: While it is clear that CTC numbers and gene expression were prognostic for PCa post-docetaxel treatment, and CTC subtype analysis may have additional value, their potential predictive value for docetaxel chemotherapy response needs to be further investigated in large patient cohorts. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Measurements of cancer extent in a conservatively treated prostate cancer biopsy cohort
- Author
-
Rajab, Ramzi, Fisher, Gabrielle, Kattan, Michael W., Foster, Christopher S., Oliver, Tim, Møller, Henrik, Reuter, Victor, Scardino, Peter, Cuzick, Jack, Berney, Daniel M., and on behalf of the Transatlantic Prostate Group
- Published
- 2010
- Full Text
- View/download PDF
4. A Validated Prognostic Index Predicting Response to Dexamethasone and Diethylstilbestrol in Castrate-Resistant Prostate Cancer.
- Author
-
Shamash, Jonathan, Stebbing, Justin, Sweeney, Chris, Sonpavde, Guru, Harland, Steve, Dawkins, Guy, Brock, Cathryn, Abelman, Walter, Wilson, Peter, Sanitt, Adam, Oliver, Tim, and Powles, Thomas
- Subjects
PROSTATE cancer treatment ,DEXAMETHASONE ,DIETHYLSTILBESTROL ,PROSTATE-specific antigen ,HORMONE therapy ,CANCER prognosis ,THERAPEUTICS - Abstract
The article discusses a study on the prognostic significance of a combined dexamethasone and diethylstilbestrol (DS) therapy by measuring the prostate-specific antigen (PSA) level before and after a month of DS therapy. An assessment of the prognostic patients factors was done 30 days after the start of DS therapy. The study indicates that the prognostic index developed showed the possibility of identifying patients with castrate-resistant prostate cancer (CRPC) who had a good prognosis within a month of DS therapy.
- Published
- 2010
- Full Text
- View/download PDF
5. Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent.
- Author
-
Kattan, Michael W., Cuzick, Jack, Fisher, Gabrielle, Berney, Daniel M., Oliver, Tim, Foster, Christopher S., Møller, Henrik, Reuter, Victor, Fearn, Paul, Eastham, James, Scardino, Peter T., Møller, Henrik, and Transatlantic Prostate Group
- Subjects
PROSTATE-specific antigen ,NOMOGRAPHY (Mathematics) ,PROSTATE cancer ,CANCER patients ,MALE reproductive organ cancer ,BIOPSY ,COMPARATIVE studies ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,PROGNOSIS ,PROSTATE tumors ,RESEARCH ,RESEARCH funding ,SURVIVAL analysis (Biometry) ,EVALUATION research ,PREDICTIVE tests ,STATISTICAL models ,DIAGNOSIS - Abstract
Background: The prognosis of men with clinically localized prostate cancer is highly variable, and it is difficult to counsel a man who may be considering avoiding, or delaying, aggressive therapy. After collecting data on a large cohort of men who received no initial active prostate cancer therapy, the aim was to develop, and to internally validate, a nomogram for prediction of disease-specific survival.Methods: Working with 6 cancer registries within England and numerous hospitals in the region, a population-based cohort of men diagnosed with prostate cancer between 1990 and 1996 was constructed. All men had baseline serum prostate-specific antigen (PSA) measurements, centralized pathologic grading, and centralized review of clinical stage assignment. Based on the clinical and pathologic data from 1911 men, a statistical model was developed and validated that served as the basis for the nomogram. The discrimination and calibration of the nomogram were assessed with use of one-third of the men, who were omitted from modeling and used as a test sample.Results: The median age of the included men was 70.4 years. The 25th and 75th percentiles of PSA were 7.3 and 32.6 ng/mL respectively, and the median was 15.4 ng/mL. Forty-two percent of the men had high-grade disease. The nomogram predicted well, with a concordance index of 0.73, and had good calibration.Conclusions: An accurate tool was developed for predicting the probability that a man with clinically localized prostate cancer will survive his disease for 120 months if the cancer is not treated with curative intent immediately. The tool should be helpful for patient counseling and clinical trial design. [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
6. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients.
- Author
-
Shaw, Greg L., Wilson, Peter, Cuzick, Jack, Prowse, David M., Goldenberg, S. Larry, Spry, Nigel A., and Oliver, Tim
- Subjects
HORMONE therapy ,PROSTATE cancer ,METASTASIS ,ANTIGENS ,THERAPEUTICS - Abstract
OBJECTIVE To review pooled phase II data to identify features of different regimens of intermittent hormone therapy (IHT), developed to reduce the morbidity of treating metastatic prostate cancer, and which carries a theoretical advantage of delaying the onset of androgen-independent prostate cancer, (AIPC) that are associated with success, highlighting features which require exploration with prospective trials to establish the best strategies for using this treatment. METHODS Individual data were collated on 1446 patients with adequate information, from 10 phase II studies with >50 cases, identified through Pubmed. RESULTS Univariate and multivariate Cox proportional hazard models were developed to predict treatment success with a high degree of statistical success. The prostate-specific antigen (PSA) nadir, the PSA threshold to restart treatment, and medication type and duration, were important predictors of outcome. CONCLUSIONS The duration of biochemical remission after a period of HT is a durable early indicator of how rapidly AIPC and death will occur, and will make a useful endpoint in future trials to investigate the best ways to use IHT based on the important treatment cycling variables described above. Patients spent a mean of 39% of the time off treatment. The initial PSA level and PSA nadir allow the identification of patients with prostate cancer in whom it might be possible to avoid radical therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
7. Risk and presenting features of prostate cancer amongst African-Caribbean, South Asian and European men in North-east London.
- Author
-
Chinegwundoh, Frank, Enver, Mohamed, Lee, Angela, Nargund, Vinod, Oliver, Tim, and Ben-Shlomo, Yoav
- Subjects
PROSTATE cancer ,RACIAL differences ,PROSTATE-specific antigen ,TUMOR antigens ,TUMOR markers ,UROLOGY ,SOUTH Asians ,EUROPEANS - Abstract
OBJECTIVE To determine whether there are ethnic differences in the incidence and presenting features of all patients with prostate cancer presenting in North-east London, UK. PATIENTS AND METHODS All newly diagnosed men with prostate cancer between 1999 and 2000 who were resident in the East London and City Health Authority were identified from various sources. Key clinical features were extracted from hospital records. The age-adjusted incidence rates for European, South Asian and African-Caribbean patients were calculated using census denominator data. RESULTS For men aged >50 years the annual age-adjusted incidence rates (95% confidence interval) were 213 (186–240), 647 (504–789) and 199 (85–310) for the European, African-Caribbean and South Asian patients, respectively. African-Caribbean men had a three times greater risk (risk ratio 3.07, 2.40–3.93, P < 0.001) than European men. South Asian men had a lower risk of prostate cancer but this could have been compatible with chance. There was no evidence of marked ethnic differences for prostate-specific antigen levels, clinical staging and Gleason scores. CONCLUSION The greater risk of prostate cancer for African-Caribbean men in South-east England is consistent with data from the USA and the Caribbean. Future work needs to determine whether this risk differs according to country of origin, and which genetic and/or environmental risk factors might be important in explaining these observations. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
8. The PROVENT study, a multicentre double blind placebo controlled randomised trial to evaluate the effects of Vitamin D and aspirin on progression of low risk prostate cancer during active surveillance.
- Author
-
Shaw, Greg, Oliver, Tim, Kealy, Roseann, Powles, Tom, Hillman, Paul, and Cuzick, Jack
- Subjects
VITAMIN D ,ASPIRIN ,PROSTATE cancer ,PLACEBOS ,PROSTATE biopsy - Published
- 2018
- Full Text
- View/download PDF
9. AN INFECTIOUS CAUSE FOR PROSTATE CANCER.
- Author
-
Radhakrishnan, Suresh, Lee, Angela, Oliver, Tim, and Chinegwundoh, Frank
- Subjects
EDITORIALS ,PROSTATE cancer risk factors ,SEX differences in cancer ,STUDY & teaching of sexually transmitted diseases ,CANCER pathophysiology ,CANCER diagnosis ,CHARTS, diagrams, etc. - Abstract
The article focuses on the risk factors of prostate cancer (PC) among men in the United Kingdom (UK). The risk factors include increasing age, race, family history of the PC patient, sexual factors and sexually transmitted diseases (STDs). A chart is also presented depicting the pathophysiological variables, sexual habits and the history of STD in men diagnosed with prostate cancer. A study to establish the role of sexual factors in the cause for PC would help educate people and prevent STDs.
- Published
- 2007
- Full Text
- View/download PDF
10. Locally Advanced and Metastatic Prostate Cancer Treated with Intermittent Androgen Monotherapy or Maximal Androgen Blockade: Results from a Randomised Phase 3 Study by the South European Uroncological Group.
- Author
-
Silva, Fernando Calais da, Silva, Fernando Manuel Calais da, Gonçalves, Frederico, Santos, Américo, Kliment, Jan, Whelan, Peter, Oliver, Tim, Antoniou, Nicos, Pastidis, Spiro, Marques Queimadelos, Anton, and Robertson, Chris
- Subjects
- *
PROSTATE cancer , *METASTASIS , *ANDROGEN receptors , *BLOCKADE , *CYPROTERONE acetate , *RANDOMIZED controlled trials - Abstract
Background: Few randomised studies have compared antiandrogen intermittent hormonal therapy (IHT) with continuous maximal androgen blockade (MAB) therapy for advanced prostate cancer (PCa). Objective: To determine whether overall survival (OS) on IHT (cyproterone acetate; CPA) is noninferior to OS on continuous MAB. Design, setting, and participants: This phase 3 randomised trial compared IHT and continuous MAB in patients with locally advanced or metastatic PCa. Intervention: During induction, patients received CPA 200 mg/d for 2 wk and then monthly depot injections of a luteinising hormone-releasing hormone (LHRH; triptoreline 11.25 mg) analogue plus CPA 200 mg/d. Patients whose prostate-specific antigen (PSA) was <4 ng/ml after 3 mo of induction treatment were randomised to the IHT arm (stopped treatment and restarted on CPA 300 mg/d monotherapy if PSA rose to ≥20 ng/ml or they were symptomatic) or the continuous arm (CPA 200 mg/d plus monthly LHRH analogue). Outcome measurements and statistical analysis: Primary outcome measurement was OS. Secondary outcomes included cause-specific survival, time to subjective or objective progression, and quality of life. Time off therapy in the intermittent arm was recorded. Results and limitations: We recruited 1045 patients, of which 918 responded to induction therapy and were randomised (462 to IHT and 456 to continuous MAB). OS was similar between groups (p = 0.25), and noninferiority of IHT was demonstrated (hazard ratio [HR]: 0.90; 95% confidence interval [CI], 0.76-1.07). There was a trend for an interaction between PSA and treatment (p = 0.05), favouring IHT over continuous therapy in patients with PSA ≤1 ng/ml (HR: 0.79; 95% CI, 0.61-1.02). Men treated with IHT reported better sexual function. Among the 462 patients on IHT, 50% and 28% of patients were off therapy for ≥2.5 yr or >5 yr, respectively, after randomisation. The main limitation is that the length of time for the trial to mature means that other therapies are now available. A second limitation is that T3 patients may now profit from watchful waiting instead of androgen-deprivation therapy. Conclusions: Noninferiority of IHT in terms of survival and its association with better sexual activity than continuous therapy suggest that IHT should be considered for use in routine clinical practice. Take Home Message: Intermittent hormone monotherapy with cyproterone acetate 300 mg/d was noninferior to maximal androgen blockade in patients with advanced prostate cancer with respect to overall survival. Intermittent therapy was also associated with greater sexual activity. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
11. Local Progression among Men with Conservatively Treated Localized Prostate Cancer: Results from the Transatlantic Prostate Group
- Author
-
Eastham, James A., Kattan, Michael W., Fearn, Paul, Fisher, Gabrielle, Berney, Daniel M., Oliver, Tim, Foster, Christopher S., Møller, Henrik, Reuter, Victor, Cuzick, Jack, and Scardino, Peter
- Subjects
- *
CANCER patients , *CANCER treatment , *THERAPEUTICS , *PROSTATE cancer treatment , *TUMOR growth , *SURGICAL excision - Abstract
Abstract: Objectives: Men with clinically detected localized prostate cancer treated without curative intent are at risk of complications from local tumor growth. We investigated rates of local progression and need for local therapy among such men. Methods: Men diagnosed with prostate cancer during 1990–1996 were identified from cancer registries throughout the United Kingdom. Inclusion criteria were age ≤76 yr at diagnosis, PSA level ≤100ng/ml, and, within 6 mo after diagnosis, no radiation therapy, radical prostatectomy, evidence of metastatic disease, or death. Local progression was defined as increase in clinical stage from T1/2 to T3/T4 disease, T3 to T4 disease, and/or need for transurethral resection of the prostate (TURP) to relieve symptoms >6 mo after cancer diagnosis. Results: The study included 2333 men with median follow-up of 85 mo (range: 6–174). Diagnosis was by TURP in 1255 men (54%), needle biopsy in 1039 (45%), and unspecified in 39 (2%). Only 29% were treated with hormonal therapy within 6 mo of diagnosis. Local progression occurred in 335 men, including 212 undergoing TURP. Factors most predictive of local progression on multivariable analysis were PSA at diagnosis and Gleason score of the diagnostic tissue (detrimental), and early hormonal therapy (protective). We present a nomogram that predicts the likelihood of local progression within 120 mo after diagnosis. Conclusions: Men with clinically detected localized prostate cancer managed without curative intent have an approximately 15% risk for local progression within 10 yr of diagnosis. Among those with progression, the need for treatment is common, even among men diagnosed by TURP. When counseling men who are candidates for management without curative intent, the likelihood of symptoms from local progression must be considered. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
12. Molecular Positron Emission Tomography and PET/CT Imaging in Urological Malignancies
- Author
-
Powles, Tom, Murray, Iain, Brock, Cathryn, Oliver, Tim, and Avril, Norbert
- Subjects
- *
POSITRON emission tomography , *TUMORS , *THERAPEUTICS , *PROSTATE cancer , *AMINO acids , *CELL proliferation - Abstract
Abstract: Objectives: Positron emission tomography (PET) provides unique insights into molecular pathways of diseases. PET using [F-18]-fluorodeoxyglucose (FDG) has gained increasing acceptance for the diagnosis, staging, and treatment monitoring of various tumour types. The aim of this review is to provide an update on the current status of molecular PET and PET/CT imaging in urological malignancies. Methods: The current literature on PET and PET/CT imaging was reviewed and summarized for prostate cancer, bladder cancer, renal cell carcinoma, and germ cell tumours. Results: Depending on the radiotracer used, PET offers diagnostic information based on glucose, choline or amino acid metabolism and has also been applied to imaging tumour cell proliferation and tissue hypoxia in urological malignancies. The diagnostic performance of FDG-PET is hampered by the renal excretion of FDG and by the low metabolic activity often seen in tumours such as prostate cancer. However, new PET tracers including radiolabelled choline and acetate may offer an alternative approach. There is consistent evidence that FDG-PET provides important diagnostic information in detecting metastatic and recurrent germ cell tumours and it might offer additional information in the staging and restaging of bladder and renal cancer. Conclusions: Although PET imaging has been shown to be a clinically useful tool, its application in urological malignancies still needs to be fully determined by larger prospective trials. The introduction of novel PET radiopharmaceuticals along with the new technology of PET/CT will likely change the future role of molecular imaging in urological malignancies. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.